Streetbeat News

Analyst Ratings

DRH

Four financial analysts have recently updated their ratings on Diamondrock Hospitality (NYSE:DRH), showing a shift towards a more positive outlook with an average 12-month price target of $10.12, up from $9.50. The company, a real estate investment trust owning lodging properties, has shown positive revenue growth, impressive net margin, and strong financial performance indicators such as ROE and ROA. However, its market capitalization is smaller compared to industry averages, and its revenue growth rate is lower than its peers in the Real Estate sector.

Portfolio Pulse from Benzinga Insights

February 23, 2024 | 2:00 pm

RRC

Range Resources (NYSE:RRC) has received mixed analyst ratings over the past three months, with a shift towards a more indifferent stance in the last 30 days. The average 12-month price target for RRC has been adjusted to $34.12, marking a 9.3% decrease from the previous target of $37.62. Analysts from firms including Truist Securities, Susquehanna, and JP Morgan have lowered their price targets, reflecting concerns over the company's recent performance and market conditions. Despite a significant revenue decline of -44.99% as of December 31, 2023, RRC demonstrates strong financial health with exceptional net margin and ROE above industry averages.

Portfolio Pulse from Benzinga Insights

February 23, 2024 | 2:00 pm

MRO

Marathon Oil (NYSE:MRO) has been evaluated by 7 analysts over the last three months, showing a mix of bullish to bearish sentiments. The average 12-month price target is now $30.29, down from $34.43, reflecting a 12.02% decline. Analysts have adjusted their ratings and price targets, indicating a cautious outlook based on Marathon Oil's financial performance, including a -11.8% revenue growth and below-industry benchmarks in ROE and ROA.

Portfolio Pulse from Benzinga Insights

February 23, 2024 | 2:00 pm

BLDR

Builders FirstSource (NYSE:BLDR) has received diverse analyst ratings over the past quarter, with a mix of bullish to bearish sentiments. Recent updates show an average 12-month price target of $191.7, reflecting an 11.64% increase from the previous target. Analysts from firms like Truist Securities, Oppenheimer, and Wedbush have raised their price targets, indicating a positive outlook on the company's performance despite a -21.3% decline in revenue growth and challenges in maintaining profitability. The company's market capitalization and financial metrics such as ROE and ROA surpass industry standards, suggesting a robust market position.

Portfolio Pulse from Benzinga Insights

February 23, 2024 | 2:00 pm

VFS

Wedbush analyst Daniel Ives reiterates an Outperform rating on VinFast Auto (NASDAQ:VFS) and maintains a $12 price target.

Portfolio Pulse from Benzinga Newsdesk

February 23, 2024 | 1:55 pm

NICE

Wedbush analyst Daniel Ives maintains an Outperform rating on NICE Systems (NASDAQ:NICE) and raises the price target from $230 to $270.

Portfolio Pulse from Benzinga Newsdesk

February 23, 2024 | 1:53 pm

ZD

Wedbush analyst Daniel Ives maintains an Outperform rating on Ziff Davis (NASDAQ:ZD) and raises the price target from $75 to $78.

Portfolio Pulse from Benzinga Newsdesk

February 23, 2024 | 1:51 pm

ZM

Zoom Video Communications (NASDAQ:ZM) has seen a 15% decline in stock price over the past year and 13.6% this year, now trading at a forward P/E of 12.56, below the sector median. JPMorgan analyst Mark R. Murphy rates ZM as Neutral with a $83 price target, indicating a 33.69% upside. Despite post-pandemic growth slowdown, Zoom's expansion into new services and a strong market position suggest an undervalued stock with over 30% upside potential. However, potential M&A activity introduces uncertainty.

Portfolio Pulse from Surbhi Jain

February 23, 2024 | 1:49 pm

IMAX

Wedbush analyst Alicia Reese reiterates an Outperform rating on Imax (NYSE:IMAX) and maintains a $22 price target.

Portfolio Pulse from Benzinga Newsdesk

February 23, 2024 | 1:49 pm

AIRS

Fuzzy Panda Research released a report on AirSculpt Technologies (AIRS), alleging serious malpractices including patient death, unqualified doctors, false advertising, and photoshopped patient images. The report claims AirSculpt's technology is not unique, accuses the company of unsafe medical practices, and states that its founder, Dr. Aaron Rollins, has suspect credentials. Fuzzy Panda Research is short AirSculpt Technologies.

Portfolio Pulse from Benzinga Newsdesk

February 23, 2024 | 1:48 pm